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Purpose: This study aimed to determine the association of ARMS2 A69S, ARMS2 
del443ins54, and CFH Y402H polymorphisms with neovascular age-related macular degen-
eration (nAMD) for the first time in an Indonesian population.
Patients and Methods: Our case–control study involved 104 nAMD and 100 control 
subjects. AMD diagnosis was evaluated by retinal specialists based on color fundus photo-
graphy and optical coherence tomography. The polymorphisms on CFH Y402H and ARMS2 
A69S were analyzed by PCR-restriction fragment length polymorphism (PCR-RFLP), 
whereas ARMS2 del443ins54 was evaluated by PCR-based assay.
Results: Significant allelic associations with nAMD were detected on all polymorphisms 
(P<0.05), with stronger association with the ARMS2 A69S (OR 3.13; 95% CI 2.08–4.71; 
P<0.001) and ARMS2 del443ins54 (OR 3.28; 95% CI 2.17–4.95; P<0.001) polymorphisms 
than with CFH Y402H (OR 2.08; 95% CI 1.08–3.99; P=0.028). Genotype analysis showed a 
statistical difference between nAMD and the control group for all polymorphisms (P<0.05). 
However, the association with nAMD was weaker for CFH Y402H (P=0.043) than for 
ARMS2 A69S and ARMS2 del443ins54 (P<0.001). A significant interaction between 
ARMS2 A69S and hypertension was documented (OR 9.53; 95% CI 3.61–25.1; P<0.001).
Conclusion: Our findings indicate that ARMS2 A69S and ARMS2 del443ins54 polymorph-
isms are strongly associated with the risk of nAMD for the first time in an Indonesian 
population. The risk of nAMD increased when the presence of risk alleles from ARMS2 
A69S was combined with the presence of hypertension.
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Introduction
Age-related macular degeneration (AMD) is a progressive degenerative disease 
affecting the macula and is the top five leading cause of irreversible blindness 
worldwide.1 It has been estimated that there are nearly 200 millions of individuals 
with AMD in 2020, and will be projected to rise to 288 millions in 2040.1
The prevalence of AMD increases exponentially with age.1 With ageing, a 
cascade of deterioration occurs in photoreceptors, retinal pigment epithelium 
(RPE) and Bruch’s membrane (BM) leaving permanent lesion observed clinically 
as geographic atrophy (dry AMD) or causing abnormal blood vessel originating 
from choroid to leak or to bleed at the macular area (neovascular AMD [nAMD]).2 
These may ultimately cause irreversible visual impairment if left untreated. 
Interestingly, studies showed that not all aged individuals undergo the similar 
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processes and develop AMD, suggesting a strong genetic- 
driven variation in the pathophysiology of this condition.3
There has been extensive literature reporting the 
genetic associations in AMD.4–6 Complement Factor H 
(CFH), Human high-temperature requirement serine pro-
tease A1 (HtrA1), and substitution from alanine to serine 
of amino acid 69 (A69S) in age-related maculopathy sus-
ceptibility 2 (ARMS2) at chromosome 10q26 are specu-
lated to play key roles in cellular senescence, thus have 
been the most consistently associated with AMD in differ-
ent populations.7–9 In previous studies, ARMS2 and HtrA1 
were reported to have a strong linkage disequilibrium.10,11 
Grassmann et al12 further asserted that the ARMS2 
rs10490924 variant (not HtrA1 rs11200638) is more 
strongly associated with AMD than HtrA1 rs11200638. 
This finding was supported by Kanda et al,10 who identify 
that ARMS2 rs10490924 polymorphism alone can explain 
the association of the 200-kb region at chromosome 10q26 
with AMD. Deletion/insertion consisting of a 443 bp dele-
tion and an adjacent 54 bp insertion in the 3ʹ-untranslated 
region (3ʹ-UTR) of ARMS2 (del443ins54) and complement 
factor H Tyr402His (CFH Y402H) was also reported to be 
strongly associated with AMD.13–15 Deletion/insertion 
polymorphism in ARMS2 disrupts the stability of ARMS2 
gene transcription products16 and induces HtrA1 transcrip-
tion regulator activity.17
In Western populations, the associations of ARMS2 and 
CFH were documented in American, Dutch, Italian, 
Spanish, and Swiss populations.14,18–23 In Asian, similar 
associations were reported in Chinese, Japanese, and 
Indian populations.15,24–27 However, very limited evidence 
is available from Asian Malay population, which is also 
one of the biggest ethnic groups in Asia.
In this study, we aimed to investigate the associations 
of ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H 
with AMD in Indonesian population, which constitutes the 
majority of Asian Malay ethnic group in the region.
Method
This was an age-matched case–control study of partici-
pants aged 45 years old or older. Cases were naïve nAMD 
patients in at least one eye attending retinal clinic at three 
tertiary hospitals in Yogyakarta: 1) Dr. Sardjito General 
Hospital; 2) Hardjolukito Military Air Force Central 
Hospital, and 3) Dr. YAP Eye Hospital with no previous 
history of AMD treatment, recruited consecutively from 
August 2016 to November 2018. The diagnosis of AMD 
was established from slit-lamp examination, fundus 
photograph and spectral-domain OCT, confirmed by a 
retinal specialist following the International Age-related 
Maculopathy (ARM) Epidemiological Study Group28 and 
AMD clinical classification criteria.29 We excluded cases 
with co-existing choroidal or other retinal inflammatory 
diseases. Controls were healthy individuals without AMD 
or other retinal lesions who underwent eye examination for 
senile cataract.
Each subject was fully informed about the purpose and 
the procedures of the study. Consent was obtained from all 
subjects in written form prior to participation. All study 
procedures adhered to the principles of the Declaration of 
Helsinki. The study was approved by the Institutional 
Review Board of Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada in August 2016.
Genotyping
The genomic DNA of each patient was extracted from 
venous blood placed into a tube containing EDTA as an 
anticoagulant. The blood samples were immediately pro-
cessed utilizing a commercially available DNA extraction 
kit (GeneAid Genomic Human DNA Mini Kit [GB100/ 
300], New Taipei City, Taiwan). DNA extraction and 
single nucleotide polymorphism (SNP) identification 
were conducted at the Integrated Research Laboratory, 
Faculty of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada.
The specific variants for the ARMS2 genes 
were ARMS2 A69S rs10490924 and ARMS2 del443ins54 
(c.*372_815del443ins54), whereas that for CFH Y402H 
was rs1061170. Polymerase chain reaction (PCR) was 
performed in a thermal cycler (ProFlex PCR System, 
Applied Biosystems) following the ready-to-use PCR 
kit protocol (KAPA Taq PCR Kit, Kapa Biosystems). 
The PCR cycling conditions were set as follows: 1 
cycle (95 °C for 2 min), 30 cycles (95 °C for 30 s), 1 
cycle (52 °C for 1 min for each gene), 1 cycle (72 °C 
for 1 min), and 1 cycle (72 °C for 5 min).
The primer sequences for the genes of interest are as 
follows: 1) ARMS2 A69S forward 5ʹ-TGTCACTGCATTC 
CCTCCTGTCAT-3ʹ and reverse 5ʹ-AAGCTTCTTACCCT 
GACTTCCAGC-3ʹ; 2) ARMS2 del443ins54 forward 5ʹ- 
TACCCAGGACCGATGGTAAC-3ʹ and reverse 5ʹ-GAG 
GAAGGCTGAATTGCCTA-3ʹ; and 3) CFH Y402H for-
ward 5ʹ-CTTTAGTTCGTCTTCAGTTATAC-3ʹ and reverse 
5ʹ-GTCATCTATGTTACTTAGAAAGT-3ʹ.
SNP identification involved PCR-based assay for 
ARMS2 del443ins54 and PCR-restriction fragment length 
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polymorphism (PCR-RFLP) for ARMS2 A69S and CFH 
Y402H. Restriction digestion was performed at 37 °C for 
18 h following the manufacturer’s protocol using PvuII 
restriction enzyme for ARMS2 A69S (Takara Bio, Japan) 
and Hsp92II for CFH Y402H (Promega). All amplified 
products were electrophoresed on 1.5% agarose gel con-
taining FloroSafe DNA stain (1st Base Asia). Random 
sampling from each genotype in each SNP was conducted 
for genotype confirmation through Sanger DNA sequen-
cing. Sequencing service was provided by 1st Base Asia, 
Singapore.
Statistical Analysis
Descriptive data were generated for all variables. Unpaired 
Student’s t-test for numerical variables or Chi-squared test 
and Fisher exact test for categorical variables was per-
formed to compare baseline characteristics between 
nAMD and control groups. Two-sided p-values were 
reported. We tested for deviation from the Hardy– 
Weinberg equilibrium (HWE) in both groups through the 
chi-square test with the “genhwcci” command in Stata.
Associations between SNP and other risk factors for 
susceptibility to nAMD were assessed using logistic 
regression models measured by odds ratio (OR) and 95% 
confidence interval (CI). In the multivariable logistic 
regression model, the likelihood ratio test was performed 
to fit the model. We pooled one risk allele and two risk 
alleles as one category (risk allele) in the interaction ana-
lysis. Interaction analysis was performed by introducing 
the interaction term in the same regression model. All 
analyses were carried out using Stata (version 15.1, 
StataCorp, College Station, TX, USA).
Results
There were 116 cases [46 males (44.2%) and 58 females 
(55.8%)] and 100 controls [45 males (45.0%) and 55 
females (55.0%)] included in the final analysis. Baseline 
characteristics of the participants are presented in Table 1. 
The mean age of cases was 66.3 ± 8.8 years while control 
was 67.9 ± 7.7 years. Cases showed very similar charac-
teristics to control except that having higher BMI (23.7 vs 
22.0; P=0.002) and were more likely to have hypertension 
(46.2% vs 18.0%; P<0.001) than controls.
The allele/genotype distributions and odds ratio (OR) 
of each SNP are summarized in Table 2. Significant allelic 
associations with nAMD were detected on all SNPs 
(P<0.05). Compared to those having non-risk alleles, 
those with risk alleles of ARMS2 A69S, ARMS2 
del443ins54, and CFH Y402H were more likely to have 
nAMD (OR 3.13; 95% Confidence Interval [CI] 2.08–4.71 
for ARMS2 A69S, OR 3.28; 95% CI 2.17–4.95 for ARMS2 
del443ins54, and OR 2.08; 95% CI 1.08–3.99 for CFH 
Y402H). Genotype analysis showed significant differences 
between the nAMD and control groups for all polymorph-
isms (Table 2). The associations of ARMS2 A69S and 
ARMS2 del443ins54 (P<0.001) with nAMD were stronger 
than that of CFH Y402H (P=0.043).
In Table 3, it is shown that homozygous risk allele 
carriers at the ARMS2 A69S polymorphism (OR 5.97; 
95% CI 2.75–13.0) and ARMS2 del443ins54 (OR 7.99; 
95% CI 3.45–18.6) were both strongly associated with 
nAMD. For CFH Y402H, individuals with one copy of 
the risk allele were more likely to have nAMD than con-
trol (OR 2.47; 95% CI 1.19–5.11). These associations 
remained significant even after controlling for age, gender, 
smoking, body mass index and blood pressure.




Range (median) 45–83 (67) 49–99 (68) 0.16
Mean ± SD 66.3 ± 8.8 67.9 ± 7.7
Sex
Male 46 (44.2%) 45 (45.0%) 0.91
Female 58 (55.8%) 55 (55.0%)
BMI (kg/m2)
Range (median) 15.2–37.1 (23.3) 15.2–36.8 (21.4) 0.002
Mean ± SD 23.7 ± 3.9 22.0 ± 4.1
BMI distribution, n
<18.5 kg/m2 41 (39.4%) 40 (40.0%) <0.001
18.5–22.9 kg/m2 6 (5.8%) 34 (34.0%)
23–24.9 kg/m2 23 (22.1%) 16 (16.0%)
>25 kg/m2 34 (32.7%) 10 (10.0%)
Sunlight exposure
Indoor workplace 73 (70.2%) 72 (72.0%) 0.78
Outdoor workplace 31 (29.8%) 28 (28.0%)
Smoking
Never 73 (70.2%) 77 (77.0%) 0.27




56 (53.8%) 82 (82.0%) <0.001
High blood pressure 48 (46.2%) 18 (18.0%)
Abbreviations: nAMD, neovascular age-related macular degeneration; SD, stan-
dard deviation; BMI, body mass index; kg/m2, kilogram/meter2.
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In additional analyses, we documented significant 
interaction between ARMS2 A69S and hypertension. 
Table 4 shows that individuals who had ARMS2 A69S 
risk alleles and hypertension had significantly higher 
odds of nAMD than those with hypertension or ARMS2 
A69S risk alleles only (OR 9.53; 95% CI 3.61–25.1; 
P<0.001).
Discussion
In this study population, we documented that gene poly-
morphisms of ARMS2 A69S and ARMS2 del443ins54 were 
strongly and independently associated with nAMD. In con-
trast, we also documented that the association of CFH 
Y402H with nAMD was weaker than that of ARMS2 A69S 
and ARMS2 del443ins54. We also documented a synergistic 
effect between ARMS2 A69S and hypertension meaning, that 
individuals with both ARMS2 A69S risk alleles and hyper-
tension had a significantly higher risk of nAMD. Findings 
from our study reconfirm that ARMS2 genes are strongly 
associated with nAMD across different populations, at the 
same time suggest the existence of gene–hypertension inter-
action between this specific gene and hypertension.
We provided the first evidence of the associations of 
ARMS2 A69S, ARMS2 del443ins54, and CFH Y402H with 
nAMD in Indonesian population. There have been several 
studies from Asian population available for direct 
comparison.15,30–32 ARMS2 A69S gene polymorphisms 
have been consistently associated with nAMD in 
Malaysian,33 Chinese Singaporean,31 Thai,30 Chinese,34,35 
Japanese,36,37 Korean,38 Indian,32 and European 
populations.39 It has also been reported that ARMS2 A69S 
has stronger associations with nAMD than CFH Y402H,40 
which is comparable to our study findings. In addition to 
ARMS2 A69S, results from our study showed that ARMS2 
del443ins54, also significantly associated with nAMD, 
which has been reported in Japanese, Caucasian, and Indian 
populations.13–15,41 In contrast to ARMS2, associations 
between CFH Y402H gene variants and nAMD have been 
less consistent.42 For example, CFH Y402H in Caucasian 
had a strong association with nAMD,4,14,43,44 but studies 
from Asian showed a conflicting result. Xu et al,34 Gotoh 
et al,45 Okamoto et al,46 Uka et al,47 and Chen et al48 showed 
a weak association of CFH Y402H with AMD while Lau 
et al49 showed a contradictory result.
The role of ARMS2 genes in nAMD has become a subject 
of interest for more than a decade.10 ARMS2 has been specu-
lated to regulate the surface complement-mediated phagocy-
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decreases of the ARMS2 expression in AMD were asso-
ciated with polymorphism of ARMS2 A69S and del443ins54. 
Decreases in ARMS2 protein would result in drusen accu-
mulation due to impaired cellular debris clearance.50 
Furthermore, a study by Yang and associates51 suggested 
that ARMS2 A69S risk allele may decrease antioxidant 
enzyme activity in end-stage AMD-specific induced pluripo-
tent stem cells(iPSCs)-derived RPE model. RPE cells are 
exposed to intense photo-oxidative energy and excess oxy-
gen, promoting reactive oxygen species (ROS). Decreases in 
antioxidant enzyme capacity lead to ROS accumulation, 
increasing oxidative damage contributed to AMD.
Some studies have suggested that inflammation may 
partly explain the link between AMD and ARMS2 
polymorphisms.25,52 In iPSCs-derived RPE from AMD 
donor, Saini et al52 showed that ARMS2 risk allele 
increased the complement proteins and pro-inflammatory 
factors compared to iPSCs-RPE derived from healthy con-
trol. In addition, there was a study reporting that ARMS2 
del443ins54 was correlated with an increase in the serum 
high sensitivity C-reactive protein (hs-CRP) levels of 
nAMD subjects in a Japanese study.25 High serum CRP 
is associated with the late stage of AMD in a systematic 
literature review and meta-analysis.53 Serum CRP repre-
sents systemic inflammatory activity and is a marker of 
chronic low-grade inflammation.53
The present study also documented gene–hypertension 
interactions of the ARMS2 A69S and hypertension. Hyman 
et al54 reported that nAMD and hypertensive disease may 
have a similar underlying systemic process, as nAMD is 
linked to high diastolic blood pressure (OR: 4.4; 95% CI: 
1.4–14.2). The involvement of oxidative stress accumula-
tion processes in both nAMD and hypertension might 
explain these associations.
The strengths of our study included age-matched cases 
and controls, detailed clinical and eye examinations by 
retinal specialist using advanced multimodal imaging to 
confirm the diagnosis of nAMD and the application of 
PCR that ensured the accuracy of genetic assessment. 
However, several limitations were also noted. First, we 
Table 3 Distribution of Unadjusted and Adjusted Odds Ratio for Risk Genotypes in ARMS2 A69S, ARMS2 Del443ins54 and CFH 
Y402H
Gene (SNP) Genotype OR (95% CI) P OR (95% CI)a P OR (95% CI)b P
ARMS2 A69S GG 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
GT 1.37 (0.64–2.92) 0.415 1.02 (0.46–2.29) 0.953 0.76 (0.30–1.94) 0.569
TT 5.97 (2.75–12.9) <0.001 5.89 (2.62–13.3) <0.001 6.82 (2.52–18.5) <0.001
ARMS2 del443ins54 wt 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
wt/indel 1.90 (0.86–4.21) 0.111 1.48 (0.65–3.38) 0.355 0.99 (0.38–2.61) 0.994
indel 7.99 (3.45–18.6) <0.001 7.39 (3.10–17.6) <0.001 7.20 (2.56–20.2) <0.001
CFH Y402H TT 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
TC 2.47 (1.19–5.11) 0.015 2.73 (1.29–5.81) 0.009 3.84 (1.42–10.4) 0.008
CC 1.15 (0.07–18.7) 0.923 0.61 (0.03–12.4) 0.751 0.94 (0.004–186) 0.982
Notes: aAdjusted for age and gender; badditionally adjusted for smoking, body mass index, and blood pressure. 
Abbreviations: wt (wild-type), non-risk allele; indel, insertion/deletion.
Table 4 Interaction Analysis of ARMS2 A69S and Hypertension
Category OR (95% CI) P-value OR (95% CI)a P-value
No hypertension & no risk allele 1.00 1.00
Hypertension only 3.90 (2.06–7.40) <0.001 4.51 (2.31–8.77) <0.001
ARMS2 A69S only 2.83 (1.44–5.56) 0.002 2.81 (1.43–5.56) 0.003
Hypertension and ARMS2 9.53 (3.61–25.1) <0.001 10.8 (4.00–28.7) <0.001
Note: aAdjusted for age and gender.
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did not use indocyanine green angiography (ICGA) as the 
gold standard for nAMD diagnosis. Nevertheless, spectral- 
domain OCT had high sensitivity and specificity in distin-
guishing nAMD from polypoidal choroidal vasculopathy 
(PCV).55–57 Diagnosis of nAMD based on fundus photo-
graphy and spectral-domain OCT had more than 90% 
agreement when compared to ICGA,58–60 thus reassuring 
the minimal bias in this study. Second, the hospital-based 
design of our study may have only captured the advanced 
profile of AMD patients, therefore limiting the representa-
tion of AMD in general population. Whether or not indi-
viduals with AMD from the general population have 
similar genetic associations remained questionable. 
Future population-based studies are warranted to address 
these questions.
In conclusion, our study highlighted a strong associa-
tion of ARMS2 A69S and del443ins54 in people with 
nAMD in Yogyakarta, Indonesia. This is the first study 
on nAMD’s genetic risk factors and the first AMD 
research in Indonesia. Limited studies have been per-
formed in Southeast Asia. Although our study found a 
weak relationship between the CFH Y402H polymorphism 
and nAMD risk, further studies are warranted to confirm 
the relationship of CFH Y402H and nAMD in Indonesian 
populations. Future work should have larger and more 
diverse sample sizes to allow subanalysis based on ethnic 
origin in Indonesia. Genetic information is important in 
the area of personalized medicine, and it may be useful as 
a baseline data to establish cohort studies of AMD clinical 
risk prediction scoring relevant to the Indonesian 
population.
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